Clinical Trials
18 trialsNCT02221310 2023-10-26
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
Phase 2 Completed
NCT00005962 2023-06-22
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00006265 2016-07-14
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00274781 2015-07-10
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
The Cleveland Clinic
Phase 2 Completed
NCT00049179 2015-03-06
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00070174 2014-02-20
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
Children's Oncology Group
Phase 2 Completed
NCT00017589 2014-01-06
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00882102 2013-09-13
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00968071 2013-03-08
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003131 2012-08-22
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
Pfizer
Phase 2 Completed
NCT00003673 2012-08-22
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Pfizer
Phase 2 Completed
NCT00006122 2012-07-16
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00077116 2012-07-16
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00089050 2011-11-30
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00008151 2010-04-02
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00037583 2009-08-21
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00044733 2006-05-18
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed